#ASCO14 - Poster: A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) vs ADT alone in non-metastatic castration-resistant prostate cancer–the SPARTAN trial

CHICAGO, IL USA (UroToday.com) - Presented by Matthew R. Smith,1 Glenn Liu,2 S. Martin Shreeve,3 Shannon Matheny,3 Antonieta Sosa,3 Thian Kheoh,3 Margaret K. Yu,3 and Eric J. Small4 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 ARN-509 smith TPS5100 thumb

1Harvard Medical School and Massachusetts General Hospital Cancer Center, Boston, MA USA
2University of Wisconsin Carbone Cancer Center, Madison, WI USA
3Janssen Research & Development, Los Angeles, CA USA
4University of California San Francisco, San Francisco, CA USA